Maze Therapeutics Announces Appointments to Its Board of Directors
Globe Newswire (Thu, 13-Aug 4:42 PM ET)
TipRanks (Thu, 13-Aug 2:00 AM ET)
TipRanks (Wed, 12-Aug 8:30 AM ET)
TipRanks (Wed, 12-Aug 7:40 AM ET)
TipRanks (Wed, 12-Aug 7:00 AM ET)
Maze Therapeutics: Buy Rating Reaffirmed as Clinical De-Risking Supports Unchanged $110 Price Target
TipRanks (Wed, 12-Aug 6:36 AM ET)
TipRanks (Wed, 12-Aug 6:25 AM ET)
Maze Therapeutics GAAP EPS of -$0.76 misses by $0.04
Seeking Alpha News (Tue, 11-Aug 4:44 PM ET)
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Globe Newswire (Tue, 11-Aug 4:01 PM ET)
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
Globe Newswire (Wed, 27-May 7:03 AM ET)
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Maze Therapeutics trades on the NASDAQ stock market under the symbol MAZE.
As of August 14, 2026, MAZE stock price declined to $26.93 with 11,403 million shares trading.
MAZE has a beta of 1.06, meaning it tends to be more sensitive to market movements. MAZE has a correlation of 0.03 to the broad based SPY ETF.
MAZE has a market cap of $1.50 billion. This is considered a Small Cap stock.
Last quarter Maze Therapeutics reported $0 in Revenue and -$.76 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.05.
The top ETF exchange traded funds that MAZE belongs to (by Net Assets): VTI, IWM, VXF, XPH, IWO.
MAZE has outperformed the market in the last year with a return of +98.0%, while the SPY ETF gained +21.9%. However, in the most recent history, MAZE shares have underperformed the stock market with its stock returning -0.1% in the last 3 month period and -2.5% for the last 2 week period, while SPY has returned +5.1% and +5.0%, respectively.
MAZE support price is $26.65 and resistance is $28.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MAZE shares will trade within this expected range on the day.